Maleic Acid → N2-(4-{4-amino-1-[1-(2-fluoroethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}-2-methoxyphenyl)-1-methyl-1H-2-indolecarboxamide, dimaleate salt

HRID 898014Notes

Reaction equation

HRID 898014 reaction equation
[NH2:1][C:2]1[N:7]=[CH:6][N:5]=[C:4]2[N:8]([CH:32]3[CH2:37][CH2:36][N:35]([CH2:38][CH2:39][F:40])[CH2:34][CH2:33]3)[N:9]=[C:10]([C:11]3[CH:16]=[CH:15][C:14]([NH:17][C:18]([C:20]4[N:21]([CH3:29])[C:22]5[C:27]([CH:28]=4)=[CH:26][CH:25]=[CH:24][CH:23]=5)=[O:19])=[C:13]([O:30][CH3:31])[CH:12]=3)[C:3]=12.[C:41]([OH:48])(=[O:47])/[CH:42]=[CH:43]\[C:44]([OH:46])=[O:45]>C(OCC)(=O)C.C(O)C>[C:41]([OH:48])(=[O:47])/[CH:42]=[CH:43]\[C:44]([OH:46])=[O:45].[C:41]([OH:48])(=[O:47])/[CH:42]=[CH:43]\[C:44]([OH:46])=[O:45].[NH2:1][C:2]1[N:7]=[CH:6][N:5]=[C:4]2[N:8]([CH:32]3[CH2:37][CH2:36][N:35]([CH2:38][CH2:39][F:40])[CH2:34][CH2:33]3)[N:9]=[C:10]([C:11]3[CH:16]=[CH:15][C:14]([NH:17][C:18]([C:20]4[N:21]([CH3:29])[C:22]5[C:27]([CH:28]=4)=[CH:26][CH:25]=[CH:24][CH:23]=5)=[O:19])=[C:13]([O:30][CH3:31])[CH:12]=3)[C:3]=12

Participants

5

Reactant 2

HCID 444266Maleic AcidHCID 22346950N2-(4-{4-amino-1-[1-(2-fluoroethyl)-4-piperidyl]-1H-pyrazolo [3,4-d]pyrimidin-3-yl}-2-methoxyphenyl)-1-methyl-1H-2-indolecarboxamide

Product 1

HCID 131725050N2-(4-{4-amino-1-[1-(2-fluoroethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}-2-methoxyphenyl)-1-methyl-1H-2-indolecarboxamide, dimaleate saltYield 80%

Reagents, catalysts & solvents 2

HCID 702EthanolCatalystHCID 8857Ethyl AcetateSolvent2×

Procedure

N2-(4-{4-amino-1-[1-(2-fluoroethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}-2-methoxyphenyl)-1-methyl-1H-2-indolecarboxamide (221 mg, 0.407 mmol) was dissolved in hot ethyl acetate (25 mL) and a few drops of ethanol. Maleic acid (94 mg, 0.814 mmol) in hot ethyl acetate (3 mL) was added. The reaction mixture was stirred at room temperature overnight. No precipitate was formed. The organic solvent was removed and the solid was triturated with ethyl acetate. The solid was collected by filtration to give N2-(4-{4-amino-1-[1-(2-fluoroethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}-2-methoxyphenyl)-1-methyl-1H-2-indolecarboxamide, dimaleate salt (252 mg, 80%). 1H NMR (DMSO-d6) δ 2.34 (m, 2H), 2.54 (m, 2H), 3.49-3.67(m, 6H), 3.96 (s, 3H), 4.04 (s, 3H), 4.81 (m, 1H), 4.92 (m, 1H), 5.06 (m, 1H), 6.14 (s, 4H), 7.16 (m, 1H), 7.34 (m, 4H), 7.60 (d, J=8.32 Hz, 1H), 7.70 (d, J=7.95 Hz, 1H), 8.14 (d, J=8.15 Hz, 1H), 8.29 (s, 1H), 9.45 (s, 1H). LCMS (Thermoquest AQA single Quad MS, Finnigan HPLC-Column: Genesis, C18, 3 um, 33×4.6 mm. Eluents: 30% B/A to 95% B/A in 4.5 min. (B: acetonitrile, A: 50 mM ammonia acetate buffer, PH 4.5), 0.8 mL/min.): RT=2.17 mm. MH+=543.3.

Workup

  1. customNo precipitate was formed
  2. customThe organic solvent was removed
  3. customthe solid was triturated with ethyl acetate
  4. filtrationThe solid was collected by filtration

Sources & evidence

ORD record
ord-49d07639df2941d483afcaa8a3c3d087
Source dataset
uspto-grants-2005_07
Patent number
US06921763B2

Reaction notes

Loading…